USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity-Based Compensation (Tables)

6 Months Ended

Jul. 04, 2015



2015		$ 3,919
2016		7,214
2017		4,843
2018		1,756
2019+		582
		$ 18,314

The cost above is expected to be recognized over a weighted-average period of 1.8 years.



	Six Months Ended

	June 28,	July 4,
	2014	2015

Expected volatility (1)	39.9%	40.6%
Risk-free interest rate (2)	1.2%	1.1%
Expected life (3)	3.54 yrs.	3.33 yrs.
Expected dividend yield (4)	0.0%	0.0%
Weighted-average exercise price (5)	$ 57.62	$ 105.27

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company’s equity awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid and currently has no plan to pay dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at January 3, 2015	1,555	$ 49.20	2.9	$ 82,564
Granted	130	105.27
Exercised	(250)	37.26
Forfeited	(18)	43.83
Expired	-	-

Outstanding at July 4, 2015	1,417	$ 56.52	2.8	$ 120,766

Exercisable at July 4, 2015	58	$ 39.33	1.9	$ 5,902